Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that it will release its first quarter 2011 financial results on Tuesday, May 3, 2011 after the closing of the U.S. financial markets. The Company will also conduct a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and highlights of the first quarter 2011.

The conference call will be available to interested parties through a live audio Internet broadcast at http://investors.somaxon.com/eventdetail.cfm. The call will also be archived and accessible at this site for approximately two weeks. Alternatively, callers may participate in the conference call by dialing (888) 549-7880 (domestic) or (480) 629-9867 (international), conference call ID 4435541. A telephonic replay will be available for approximately two weeks following the conclusion of the call by dialing (800) 406-7325 (domestic) or (303) 590-3030 (international), and entering passcode 4435541.

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Somaxon’s product Silenor ®, now available by prescription in the United States, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.

For more information, please visit the company’s web site at www.somaxon.com.

Copyright Business Wire 2010

If you liked this article you might like

Somaxon Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Transcept Wins Sleeping Pill Approval

Transcept Wins Sleeping Pill Approval

Biotech Stock Mailbag: Somaxon, Transcept

Biotech Stock Mailbag: Somaxon, Transcept

Biotech Stock Mailbag: Generex Bio

Biotech Stock Mailbag: Generex Bio

Biotech Stock Mailbag: Avanir Pharma

Biotech Stock Mailbag: Avanir Pharma